Previous Article | Next Article ![]()
Infection and Immunity, May 2000, p. 2728-2734, Vol. 68, No. 5
Parasitology Research Center, Department of
Pathology, Tufts University School of Medicine,1
and Department of Pathology, Tufts University School of
Veterinary Medicine, and New England Medical
Center,2 Boston, Massachusetts 02111;
Department of Biological Chemistry and Molecular
Pharmacology, Harvard Medical School, Boston, Massachusetts
021153; and Department of Molecular
Microbiology, Washington University School of Medicine, St. Louis,
Missouri 631104
Received 29 November 1999/Returned for modification 11 January
2000/Accepted 4 February 2000
Earlier studies showed that mice primed for a few hours with the
trans-sialidase (TS) of Trypanosoma cruzi, the
agent of Chagas' disease, become highly susceptible to trypanosomal
infection. These studies suggest that TS affects parasite virulence
independent of antigenic stimulation. Potentially, TS could enhance or
reduce the virulence of heterologous microbes depending on the
mechanism of TS action and on the type of immune response elicited by
the particular parasite. We tested this hypothesis by expressing
heterologous TS in Leishmania major, a protozoan parasite
that causes cutaneous leishmaniasis and lacks TS and the TS product
The flagellate protozoan
Trypanosoma cruzi, the agent of Chagas' disease, invades
cells in the form of trypomastigotes. Inside the host cell, parasites
escape from the initial vacuole into the cytoplasm, where they develop
into amastigotes, which, after several cycles of multiplication,
differentiate back into the invasive trypomastigotes. Upon exiting
infected cells, trypomastigotes may invade adjacent cells by migration
through the extracellular matrix or distant cells through the
circulation. Coincident with the intracellular
amastigote-trypomastigote differentiation is the expression of
trans-sialidase (TS), an enzyme that specifically hydrolyzes
Several lines of evidence implicate TS as a direct mediator of T. cruzi-host cell interactions (27). First, surface
membrane-bound TS promotes trypomastigote adhesion to host cells by
direct interaction with sialyl epitopes present on the host cell plasma
membrane (14, 28). Such adhesion is thought to be a
consequence of the sialic acid-binding lectin activity of TS, which
occurs in an environment containing relatively low concentrations of
terminal nonreducing Other experiments suggest that TS promotes invasion without directly
affecting T. cruzi penetration of mammalian cells.
Specifically, mice sensitized with TS become highly permissive hosts
for T. cruzi (3). In fact, TS sensitization could
turn a nonlethal dose of T. cruzi into a mortal one
(3). The low dosage (nanograms per mouse) and timing (1 to
2 h before parasite inoculation) of TS sensitization suggested
that the enzyme enhanced virulence by altering the dynamics of innate
and/or acquired immune responses to T. cruzi, independent of
antigenic stimulation of B- and T-cell receptors. Accordingly, TS did
not effectively potentiate parasitemia in immune-deficient mice
(3).
It stands to reason that if TS sabotages the mouse defenses to spur
T. cruzi growth, then TS might enhance or reduce virulence in other parasite infections as well. To test this hypothesis, we
expressed TS in Leishmania major, a protozoan parasite that causes cutaneous leishmaniasis. We chose L. major because it
elicits a well-characterized immune response in mammalian hosts,
particularly mice (11, 22). Moreover, these parasites can be
readily modified genetically, yielding lines which express high levels
of exogenous transgenes (7, 12). Thus, Leishmania
offers a convenient background on which to assay the function of
specific T. cruzi virulence factors independent of other
T. cruzi determinants. Our results show that transgenic
L. major expressing TS becomes extremely virulent to mice
and that the ectopically expressed trypanosomal enzyme is the cause of
the enhanced virulence.
Parasite culture.
All studies were performed with the cloned
L. major strain Friedlin V1 (MHOM/IL/80/Friedlin).
Promastigotes were maintained at 26°C in medium M199 (Gibco-BRL)
supplemented with 10% heat-inactivated fetal calf serum, 20 mM HEPES
(pH 7.4), 1% penicillin-streptomycin (Cellgro), 0.01% adenine
(Sigma), 0.0004% hemin, and 0.1% biotin (Sigma) (10).
Parasites were subcultured every 3 to 4 days at a 1:100 dilution. To
prepare inocula for animal studies, parasites were grown in NNN medium
supplemented with 20% heat-inactivated fetal calf serum overlying a
solid phase composed of 3% nutrient agar, 0.6% NaCl, 10%
defibrinated sheep blood, and 0.3% glucose (30). Under
these conditions, densities in excess of 5 × 107
parasites per ml could be obtained.
Leishmania expression construct for T. cruzi TS.
DNA from the T. cruzi TS-containing
plasmid 19Y (4, 18) was digested with SmaI and
XhoI. The expected 3.8-kb DNA fragment encoding the
full-length TS protein was purified and inserted into
SmaI-cut plasmid pXG1a (2, 12), yielding pXG-TS.
DNA from pXG1a and pXG-TS were prepared with the Qiagen Maxiprep kit.
Transfection of Leishmania.
Plasmid DNAs (40 µg) for
either pXG-TS or the pXG1a vector were transfected by electroporation
into 4 × 107 logarithmic-phase L. major V1
promastigotes as described before (10) except that
promastigotes were plated onto semisolid M199 medium containing G418
(16 µg/ml). After incubation at 26°C for 7 days, single colonies
(L1, L2, and L3 for pXG-TS, Lv for pXG1a) were picked into 1 ml of M199
lacking drug, incubated at 26°C to a density of 106 to
107/ml, and then transferred into 10 ml of growth medium
containing G418 (10 µg/ml).
TS assays.
Promastigotes were cultured for 5 days to reach
the stationary phase and then centrifuged at 1,250 × g
for 10 min to give a supernatant (conditioned medium in Fig. 1B) and a
cell pellet, which was washed twice with 0.01 M sodium phosphate buffer
(PBS, pH 7.2) and resuspended in the same buffer at 108
parasites per ml. TS activity in cell lysates and conditioned medium
was determined as described before (29).
Western blot analysis.
Stationary-phase promastigotes were
washed twice with PBS (pH 7.2) and resuspended at 2 × 108/ml in PBS (pH 7.2) containing 1% Triton X-100 and
protease inhibitors (10 µM pepstatin A, 0.1 mM iodoacetamide, 10 µM
leupeptin, 10 µg of soybean trypsin inhibitor per ml, and 1 mU of
aprotinin per ml [all from Sigma]). Conditioned medium was
concentrated 10-fold using Biomax filters (Millipore) with a 50-kDa
cutoff. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis,
transfer to nitrocellulose, and TS detection with TCN-2 were performed as described previously (20).
Analysis of infection in vivo.
Groups of three to five
female BALB/c or C57BL/6 mice (Jackson Laboratory, Bar Harbor, Maine),
4 to 6 weeks old, were injected subcutaneously in the footpad with
106 stationary-phase L. major L1 and Lv
promastigotes (i.e., 14 to 17 days in culture). Most stationary-phase
promastigotes were metacyclic promastigotes, as determined by peanut
agglutinin binding (25). Cutaneous lesions produced by the
inocula were monitored weekly by measuring the thickness of the
infected footpad with a Vernier caliper and calculating the difference
against uninfected-footpad measurements (30). The thickness
of the uninfected contralateral footpad was measured as a control. The
number of parasites in the footpad lesion was calculated by a modified
limiting-dilution analysis of a single-cell suspension from individual
excised lesions (12, 30). In brief, single-cell suspensions
of the lesions from three mice at 4 weeks postinoculation were plated
in Grace's medium in triplicate, and the mean of the negative log
parasite titer was calculated 6 days after the start of the cultures.
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Heterologous Expression of Trypanosoma cruzi
trans-Sialidase in Leishmania major Enhances
Virulence


![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
2-3-linked sialic acid. Leishmania cells transfected
with a T. cruzi TS expression construct made high levels of
active enzyme, which was present in the promastigotes and shed into the
extracellular milieu. TS expression did not affect L. major
binding to and entry into cultured macrophages or its tropism for
macrophage infection in vivo. However, TS-expressing L. major exhibited elevated virulence in BALB/c mice, as determined
by lesion progression, parasite numbers, and macro- and microscopic
examination of cutaneous lesions. Several genetic tests proved that the
enhanced virulence was directly attributable to TS expression. The
results are consistent with TS functioning to sabotage the mouse immune
system to confer a growth advantage on T. cruzi and
transgenic L. major. These data suggest that heterologous
expression of T. cruzi virulence factors in
Leishmania may provide a new approach for dissecting their function in vivo.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
2,3-linked sialic acid (neuraminidase or sialidase activity)
(17) and transfers the sialic acid to
-galactosidase acceptors (transferase activity) (16, 26, 29; for a
review, see reference 27). Both host and parasite
glycoconjugates can act as substrates for TS. TS is anchored to the
outer membrane of trypomastigotes by a glycophosphoinositol (GPI)
moiety (18, 23) and is readily shed into the extracellular
environment by the action of specific phospholipases (23).
-galactosidase residues, as in the
glycoconjugate-containing outer membrane of mammalian cells
(29). Second, extracellular trypomastigotes can be
classified into two populations, a minor subset of 20 to 30% with
relatively high TS activity (TS+ parasites), and a major
subset with relatively low or no TS expression (TS
parasites) (19). In vitro, TS+ trypomastigotes
are much better than the TS
parasites in adhering to and
invading cells (19). What's more, the TS+
parasites exhibit greater virulence than the counterpart
TS
parasites do for BALB/c mice (19). The
importance of TS in T. cruzi invasion was underscored by the
ability of exogenous enzyme to switch the less invasive
TS
parasites to the highly invasive TS+
phenotype (19). Lastly, soluble and membrane-bound TS is
thought to facilitate the rupture of the phagolysosomal membrane, which would allow the parasite to escape into the cytoplasm for completion of
the intracellular cycle (8).
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
Immunofluorescence. Promastigotes were washed three times in PBS (pH 7.2), fixed in 4% paraformaldehyde for 1 min at room temperature, and washed with H2O. The parasites were incubated with 1% bovine serum albumin and 1% goat serum (Boehringer Mannheim) in PBS (pH 7.2) (buffer A) for 1 h at room temperature to block nonspecific binding. Primary antibody (protein G-purified TCN-2 monoclonal antibody [MAb], immunoglobulin G1 [IgG1] subtype) (20) was added to the cells for 1 h at a concentration of 1.7 µg/ml, followed by washing with PBS (pH 7.2) and addition of fluorescein 5-isothiocyanate-conjugated goat anti-mouse IgG (Boehringer Mannheim), as described previously (20).
Cloning of L1 parasites from BALB/c mouse lesions. Five BALB/c mice were infected with L1 and Lv promastigotes and sacrificed by CO2 asphyxia when the footpads were 4 to 5 mm in circumference for the L1-infected mice (~4 weeks postinoculation). The cutaneous lesions were dissected, homogenized in a tissue grinder, resuspended in M199 medium, and centrifuged at 500 rpm for 5 min to yield a supernatant enriched in amastigotes. The parasites were then cloned in four 96-well microtiter plates at a density of 0.25 parasites per well in growth medium without G418. When clonal growth was evident by light microscopy (minimum of 10 promastigotes per well), the parasites in each well were resuspended and subdivided into two aliquots. One was placed in another well containing growth medium without G418, and the other aliquot was placed in another well containing G418 (10 µg/ml). After 1 to 2 weeks, parasites from wells showing growth were recovered, and cultures were expanded for subsequent studies.
| |
RESULTS |
|---|
|
|
|---|
Expression of T. cruzi TS in L. major. We constructed an expression system for the T. cruzi TS in L. major using the constitutive expression vector pXG1a (7, 10) containing the full-length coding region for TS (4, 18). pXG1a is an expression vector containing the Leishmania splice acceptor and flanking sequences required to direct gene expression in both the promastigote and amastigote stages of the Leishmania life cycle. Following transfection of the pXG-TS construct into Leishmania, we selected three independent clonal lines for further study (L1, L2, and L3). Additionally, a control line (Lv) was obtained following transfection with the empty vector pXG1a.
Evidence of TS expression in L. major was provided by direct measurement of enzymatic activity in the parasites and in the medium conditioned by Leishmania growth. Lysates of clones L1, L2, and L3 had relatively high TS activity, about 30 to 60% of the specific enzymatic activity of T. cruzi trypomastigotes (Silvio strain), while lysates of clone Lv had no detectable TS activity (Fig. 1A). The heterologously expressed TS was released into the culture medium (Fig. 1B), as observed with T. cruzi (14, 23).
|
Enhanced virulence of TS-expressing L. major
promastigotes.
The TS-expressing L1, L2, and L3 promastigotes grew
in liquid medium at the same rate as the control Lv promastigotes (data not shown). Likewise, there was no detectable difference in the generation of metacyclic promastigotes in stationary-phase L1 and Lv
cultures, as determined by peanut agglutinin binding (data not shown).
However, L1 promastigotes, upon inoculation in the footpads of
genetically susceptible BALB/c mice, were much more effective than Lv
promastigotes in producing local swelling (Fig. 2A and C). Most BALB/c mice died 4 to 6 weeks after inoculation with 106 L1 promastigotes, while
all mice survived at least 18 weeks after inoculation with the same
number of Lv promastigotes (data not shown). In addition, C57BL/6 mice,
which are genetically resistant to L. major infection
(15), exhibited a cutaneous swelling upon infection with
TS-expressing L1 but not control Lv promastigotes (Fig.
3). However, the L1-induced swelling in
the C57BL/6 mice was transient, contrary to the infection in the
susceptible BALB/c mice (Fig. 2 and 3). This is similar to the lesion
progression typically seen in resistant mice except that the degree of
swelling was much greater. The tissues in the L1-inoculated sites of
BALB/c mice had TS activity weeks after parasite inoculation, while the tissues of Lv-inoculated sites did not (Fig. 2B). This indicates that
L1 parasites express TS in vivo.
|
|
|
Direct correlation of TS expression in L. major with
enhancement of virulence.
To directly implicate TS in the
enhancement of virulence, we took advantage of the instability of
episomal expression constructs such as pXG1a in the absence of
continued drug pressure for maintenance of the selective marker
(2, 12). This allowed us to generate segregants from the
highly virulent TS-expressing L1 line, which now lacked TS. First, a
series of clonal lines were obtained in the absence of selective drug
(G418 for the neo marker of pXG1a) from amastigotes derived
from the prominent lesions of L1-infected BALB/c mice. Of the 15 lines
examined, 14 had lost the pXG-TS plasmid and were now G418 sensitive,
while 1 retained G418 resistance (line L1G5). Accordingly, lysates of
L1G5 promastigotes expressed TS at levels similar to that of parental
L1 promastigotes (Fig. 5A), while the
other 14 G418-sensitive subclones, such as L1D4, did not have
detectable TS activity (Fig. 5A).
|
| |
DISCUSSION |
|---|
|
|
|---|
TS expressed by L. major is located either in the parasites, most likely on the outer membrane (Fig. 1D), or in the extracellular milieu as a soluble factor (Fig. 1B). Such location is similar to that of endogenous TS of T. cruzi, which is anchored to the trypomastigote plasma membrane through a GPI linkage (18, 23) and thus is readily shed into the extracellular environment. It is likely that ectopic TS also attaches to the L. major surface by a GPI anchor, because the TS gene introduced into the promastigotes contains a predicted GPI anchor motif. Consistent with this expectation, addition of exogenous GPI-specific lipase to L1 promastigotes increased the release of TS (M. Herrera and M. A. Pereira, unpublished observations). Thus, like the endogenous TS of T. cruzi, heterologously expressed TS is strategically located for a possible role in modifying the outcome of L. major interactions with a host.
Earlier results showed that surface-bound TS mediates attachment of T. cruzi trypomastigotes to epithelial and fibroblast host cells (14, 28). However, TS-expressing Leishmania cells were not better than control promastigotes in invading macrophages, at least the mouse macrophage cell line RAW 264.7. In addition, TS-expressing promastigotes did not bind to cultured cells that are not normally invaded by Leishmania, specifically epithelial cells (mink lung epithelial cells) and fibroblasts (Vero cells) (M. B. Carrillo and M. A. Pereira, unpublished observations). Similarly, L. major was not detected in any cell type other than macrophages of L1-infected mice. These results suggest that ectopic TS does not override the molecular mechanisms underlying direct L. major binding to and invasion of target host cells.
Remarkably, ectopic TS was highly effective in boosting the virulence of the transgenic parasites for BALB/c mice, as detected by increased lesion size and elevated parasite numbers therein (Fig. 2, 4, and 5). This was shown genetically in two ways. First, TS-expressing L1 promastigotes induced greater cutaneous lesions than control vector-transfected Lv promastigotes (Fig. 2), ruling out transfection-associated effects. Second, segregants from L1 parasites either retained or lost pXG-TS and TS expression: those that retained TS expression maintained their enhanced virulence in BALB/c mice, while those that lost the plasmid and TS expression lost the enhanced-virulence phenotype (Fig. 5A and B). As expected, reintroduction of pXG-TS into the Leishmania parasites restored TS expression (Fig. 5A) concurrently with the enhanced virulence of parental L1 promastigotes (Fig. 5C). Thus, these data show that expression of TS, and only expression of TS, is the cause for the enhanced-virulence phenotype. In this regard, TS expression satisfies the "molecular" Koch's postulates for establishment as a virulence factor (1, 6).
The TS-provoked enhancement of virulence of L. major supports earlier findings showing that mice sensitized with TS become highly susceptible to T. cruzi infection (3). The timing (1 to 2 h prior to T. cruzi inoculation) and low dose of TS priming and the reduced enhancement of virulence in mice with functionally deficient lymphocytes suggest that TS augmented T. cruzi virulence by subverting the host immune system. Such a hypothesis could also explain the augmented virulence of TS-expressing L. major reported here, particularly because TS does not seem to play a role in Leishmania invasion of macrophages in vitro.
How might TS sabotage the mouse immune system to allow greater
expansion of L. major? One provocative possibility is for TS to trigger cytokine release in normal cells independent of B- and
T-cell receptor activation, which should upset the balance of normal
immune response patterns. It has been established that the
susceptibility of BALB/c mice to L. major is determined
principally by an upregulation of the anti-inflammatory cytokine
interleukin-4 (IL-4) and a downregulation of the proinflammatory
cytokine gamma interferon (IFN-
) (13). Thus, in theory,
TS could enhance L. major infection in BALB/c mice by
further upregulating interleukin-4 and downregulating IFN-
in mice
infected with L1 promastigotes relative to mice infected with Lv parasites.
This hypothesis could indeed be the case, because we found that the
level of IL-4 but not IFN-
secreted by splenocytes from L1-infected
mice in response to TS was about 10 times higher than the IL-4 level
secreted by splenocytes from Lv-infected mice (W. Gao and M. A. Pereira, unpublished results). Thus, the greater virulence of L1
parasites relative to the Lv counterparts could be due to enhanced
TS-driven Il-4 secretion. The interleukin-secretory power of TS was
recently demonstrated in normal human cells, specifically intestinal
microvascular endothelial cells and peripheral blood mononuclear cells,
which secrete IL-6 in response to TS (24). A further link
between TS and cytokine pathways is evident by the cooperation of the
trypanosomal enzyme with ciliary neurotrophic factor and leukemia
inhibitory factor, two IL-6 family members, to promote survival of
neuronal cells under conditions in which the cells would otherwise die
of apoptosis induced by growth factor starvation (5).
It is therefore possible that the power of TS to induce multiple cytokines in naive and immune cells and to synergize with bona fide cytokines should serve to undermine innate and/or acquired immune responses and allow the parasite to thrive in the mammalian host. However, it remains to be determined whether L1 organisms will alter the normal immune response to the leishmanial parasites. Because L. major elicits a well-characterized immune response (11, 22), infection of mice with TS-expressing L. major should prove useful to test the new concept that TS is able to sabotage the immune system to promote T. cruzi growth in vivo (3, 24).
| |
ACKNOWLEDGMENTS |
|---|
We thank David Russell for discussions, Julia Guzova for performing several DNA transfections, and Lynne Garrity for participating in the initial experiments.
This work was supported by NIH grants AI 18102 (to M.A.P.) and AI 29646 (to S.M.B.).
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Pathology, Parasitology Research Center, Tufts Medical School, 136 Harrison Avenue, Boston, MA 02111. Phone: 617-636-2933. Fax: 617-636-6849. E-mail: maperrin{at}yahoo.com.
Present address: The Center for Blood Research, Department of
Pathology, Harvard Medical School, Boston, MA 02115.
Present address: Millennium Pharmaceuticals, Inc., Cambridge,
MA 02139.
Editor: J. M. Mansfield
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Beverley, S. M. 1996. Hijacking the cell: parasites in the driver's seat. Cell 78:787-789. |
| 2. |
Chakkalath, H. R.,
A. A. Siddiqui,
A. H. Shankar,
D. E. Dobson,
S. M. Beverley, and R. G. Titus.
2000.
Priming of a -galactosidase ( GAL)-specific type 1 response in BALB/c mice infected with GAL-transfected Leishmania major.
Infect. Immun.
68:809-814 |
| 3. |
Chuenkova, M., and M. E. A. Pereira.
1995.
Trypanosoma cruzi trans-sialidase: enhancement of virulence in a murine model of Chagas' disease.
J. Exp. Med.
181:1693-1703 |
| 4. | Chuenkova, M., M. Pereira, and G. Taylor. 1999. trans-Sialidase of Trypanosoma cruzi: location of galactose-binding site(s). Biochem. Biophys. Res. Commun. 262:549-556[CrossRef][Medline]. |
| 5. | Chuenkova, M., and M. A. Pereira. 2000. A trypanosomal protein synergizes with the cytokines CNTF and LIF to prevent apoptosis in neuronal cells. Mol. Biol. Cell, in press. |
| 6. | Falkow, S. 1988. Molecular Koch's postulates applied to microbial pathogenicity. Rev. Infect. Dis. 10:S274-S276. |
| 7. | Ha, D. S., J. K. Schwarz, S. J. Turco, and S. M. Beverley. 1996. Use of the green fluorescent protein as a marker in transfected Leishmania. Mol. Biochem. Parasitol. 77:57-64[CrossRef][Medline]. |
| 8. |
Hall, B. F.,
P. Webster,
A. K. Ma,
K. A. Joiner, and N. W. Andrews.
1992.
Desialylation of lysosomal membrane glycoproteins by Trypanosoma cruzi: a role for the surface neuraminidase in facilitating parasite entry into the host cell cytoplasm.
J. Exp. Med.
176:313-325 |
| 9. |
Hamer, D. H.,
H. Ward,
S. Tzipori,
M. E. Pereira,
J. P. Alroy, and G. T. Keusch.
1994.
Attachment of Cryptosporidium parvum sporozoites to MDCK cells in vitro.
Infect. Immun.
62:2208-2213 |
| 10. |
Kapler, G. M.,
C. C. Coburn, and S. M. Beverley.
1990.
Stable transfection of the human parasite Leishmania delineates a 30-kb region sufficient for extrachromosomal replication and expression.
Mol. Cell. Biol.
10:1084-1094 |
| 11. | Launois, P., F. Tacchini-Cottier, C. Parra-Lopez, and J. A. Louis. 1988. Cytokines in parasitic diseases: the example of cutaneous leishmaniasis. Int. Rev. Immunol. 17:157-180. |
| 12. |
LeBowitz, J. H.,
C. M. Coburn,
D. McMahon-Pratt, and S. M. Beverley.
1990.
Development of a stable Leishmania expression vector and application to the study of parasite surface antigen genes.
Proc. Natl. Acad. Sci. USA
87:9736-9740 |
| 13. | Locksley, R. M., S. Pingel, D. Lacy, A. E. Wakil, M. Bix, and D. J. Fowell. 1999. Susceptibility to infectious diseases: Leishmania as a paradigm. J. Infect. Dis. 179:S305-S308. |
| 14. | Ming, M., M. Chuenkova, E. Ortega-Barria, and M. E. A. Pereira. 1993. Mediation of Trypanosoma cruzi invasion by sialic acid on the host cell and trans-sialidase on the trypanosomes. Mol. Biochem. Parasitol. 59:243-252[CrossRef][Medline]. |
| 15. | Mitchell, G. F. 1983. Murine cutaneous leishmaniasis: resistance in reconstituted nude mice and several F1 hybrids infected with Leishmania tropica major. J. Immunogenet. 10:395-412[Medline]. |
| 16. | Parodi, A. J., G. D. Pollevick, M. Mautner, A. Buschiazzo, D. O. Sanchez, and A. C. C. Frasch. 1992. Identification of the gene(s) coding for the trans-sialidase of Trypanosoma cruzi. EMBO J. 11:1705-1710[Medline]. |
| 17. |
Pereira, M. E. A.
1983.
A developmentally regulated neuraminidase activity in Trypanosoma cruzi.
Science
219:1444-1447 |
| 18. |
Pereira, M. E. A.,
J. S. Mejia,
E. Ortega-Barria,
D. Matzilevich, and R. P. Prioli.
1991.
The Trypanosoma cruzi neuraminidase contains sequences similar to bacterial neuraminidases, YWTD repeats of the low-density lipoprotein receptor, and type III modules of fibronectin.
J. Exp. Med.
174:179-191 |
| 19. | Pereira, M. E. A., K. Zhang, Y. Gong, E. M. Herrera, and M. Ming. 1996. Invasive phenotype of Trypanosoma cruzi restricted to a population expressing trans-sialidase. Infect. Immun. 64:3884-3892[Abstract]. |
| 20. | Prioli, R. P., J. S. Mejia, and M. E. A. Pereira. 1990. Monoclonal antibodies against Trypanosoma cruzi neuraminidase reveal enzyme polymorphism, recognize a subset of trypomastigotes, and enhance infection in vitro. J. Immunol. 144:4384-4391[Abstract]. |
| 21. | Prioli, R. P., E. Ortega-Barria, J. S. Mejia, and M. E. A. Pereira. 1992. Mapping of a B-cell epitope present in the neuraminidase of Trypanosoma cruzi. Mol. Biochem. Parasitol. 52:85-96[CrossRef][Medline]. |
| 22. | Reiner, S. L., and R. M. Locksley. 1995. The regulation of immunity to Leishmania major. Annu. Rev. Immunol. 13:151-177[CrossRef][Medline]. |
| 23. | Rosenberg, I., R. P. Prioli, E. Ortega-Barria, and M. E. A. Pereira. 1991. Stage-specific phospholipases C mediated release of Trypanosoma cruzi neuraminidase. Mol. Biochem. Parasitol. 46:303-306[CrossRef][Medline]. |
| 24. |
Saavedra, E.,
M. Herrera,
W. Gao,
H. Uemura, and M. A. Pereira.
1999.
The Trypanosoma cruzi trans-sialidase, through its COOH-terminal tandem repeat, up-regulates interleukin-6 secretion in normal human intestinal microvascular endothelial cells and peripheral blood mononuclear cells.
J. Exp. Med.
190:1825-1836 |
| 25. |
Sacks, D., and P. V. Perkins.
1984.
Identification of an infective stage of Leishmania promastigotes.
Science
223:1417-1419 |
| 26. |
Schenkman, S. L.,
P. de Carvalho, and V. Nussenzweig.
1992.
Trypanosoma cruzi trans-sialidase and neuraminidase activities can be mediated by the same enzyme.
J. Exp. Med.
175:567-575 |
| 27. | Schenkman, S., D. Eichinger, M. E. A. Pereira, and V. Nussenzweig. 1994. Structural and functional properties of trypanosoma trans-sialidase. Annu. Rev. Microbiol. 48:499-532[Medline]. |
| 28. |
Schenkman, R. P.,
F. Vandekerckhove, and S. Schenkman.
1993.
Mammalian cell sialic acid enhances Trypanosoma cruzi invasion.
Infect. Immun.
61:898-902 |
| 29. |
Scudder, P.,
J. P. Doom,
M. Chuenkova,
I. D. Manger, and M. E. A. Pereira.
1993.
Enzymatic characterization of the -D-galactoside 2,3-trans-sialidase from Trypanosoma cruzi.
J. Biol. Chem.
268:9886-9891 |
| 30. |
Titus, R. G.,
F. J. Gueiros-Filho,
L. A. R. de Freitas, and S. M. Beverley.
1995.
Development of safe live Leishmania vaccine lines by gene replacement.
Proc. Natl. Acad. Sci. USA
92:10267-10271 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|